2001 Fiscal Year Final Research Report Summary
Developmental study on anti-dementia drugs by using neuropeptides related to memory disturbance
| Project/Area Number |
11672197
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Meijo University |
|---|
Principal Investigator |
UKAI Makoto Meijo University, Faculty of Pharmacy, Professor, 薬学部, 教授 (80131209)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANEMATSU Ken Meijo University, Research Institute, Director, 総合研究所, 所長 (70023041)
|
|---|
| Project Period (FY) |
1999 – 2001
|
| Keywords | Endomorphin / Opioid / Opioid receptor antagonist / Anti-dementia drug / Short-term memory / Long-term memory / Neuropeptide / Dementia |
|---|
| Research Abstract |
The effects of the μ-opioid receptor agonists endomorphin-1 and -2 on short- and long-term memory were examined. In addition, the present study was designed to find novel therapeutic drugs for dementia. The μ-opioid receptor antagonist β-funaltrexamine significantly antagonized the endomorphins-induced disturbance of short- and long-term memory. Although the disturbance of short-term memory with endomorphm-1 was significantly improved by the μ1-opioid receptor antagonist naloxonazine, such drug was without any significant effects on the endomorphin-2-induced disturbance of short-term memory. Naloxonazine and the cholmesterase inhibit or physostigmine ameliorated the disturbance of long-term memory. The dopamine D2 receptor agonist RU24213 did not significantly influence the disturbance of short- and long-term memory induced by endomorpnms, the dopamine D2 receptor antagonist (-)-sulpiride significantly antagonized the endomorphins-induced disturbance of short- and long-term memory. From the above results, μ1-opioid receptor, dopamine D2 receptor and cholinergic neurotransmission play a major role in the memory disturbance with endomorpnins. Furthermore, it is possible that μ1-opioid receptor antagonists are useful as novel anti-dementia drugs.
|
